Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Compass Therapeutics stock
Learn how to easily invest in Compass Therapeutics stock.
Compass Therapeutics Inc. is a biotechnology business based in the US. Compass Therapeutics shares (CMPX) are listed on the NASDAQ and all prices are listed in US Dollars. Compass Therapeutics employs 24 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Compass Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CMPX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Compass Therapeutics stock price (NASDAQ: CMPX)Use our graph to track the performance of CMPX stocks over time.
Compass Therapeutics shares at a glance
|Latest market close||$2.28|
|52-week range||$1.25 - $4.38|
|50-day moving average||$2.84|
|200-day moving average||$2.41|
|Wall St. target price||$9.17|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-1.09|
Buy Compass Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Compass Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Compass Therapeutics price performance over time
|1 week (2022-09-23)||1.79%|
|1 month (2022-09-01)||-21.38%|
|3 months (2022-07-01)||-13.96%|
|6 months (2022-04-01)||54.05%|
|1 year (2021-10-01)||-35.04%|
|2 years (2020-09-27)||N/A|
|3 years (2019-09-27)||N/A|
|5 years (2017-09-27)||N/A|
Compass Therapeutics financials
|Gross profit TTM||$0|
|Return on assets TTM||-24.17%|
|Return on equity TTM||-44.43%|
|Market capitalisation||$233 million|
TTM: trailing 12 months
Compass Therapeutics share dividends
We're not expecting Compass Therapeutics to pay a dividend over the next 12 months.
Compass Therapeutics overview
Compass Therapeutics, Inc. , a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts. .
Compass Therapeutics in the news
Compass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
Frequently asked questionsWhat percentage of Compass Therapeutics is owned by insiders or institutions?
Currently 10.919% of Compass Therapeutics shares are held by insiders and 61.121% by institutions. How many people work for Compass Therapeutics?
Latest data suggests 24 work at Compass Therapeutics. When does the fiscal year end for Compass Therapeutics?
Compass Therapeutics's fiscal year ends in December. Where is Compass Therapeutics based?
Compass Therapeutics's address is: 80 Guest Street, Boston, MA, United States, 02135 What is Compass Therapeutics's ISIN number?
Compass Therapeutics's international securities identification number is: US20454B1044
More guides on Finder
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
Ask an Expert